SCHEMBL2632833

SCHEMBL2632833

CCC(C)C(=O)Oc1ccncc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.43
LMNA P02545 4/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP19A1 P11511 3/20 0.41
ELANE P08246 2/20 0.41
KMT2A Q03164 2/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MAPT P10636 2/20 0.40
MAPK1 P28482 1/20 0.40
ESR1 P03372 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28332489 0.84 HSD17B10 (0.44) HSD17B10LMNACYP1A2CYP2C9CYP2C19
SCHEMBL25968326 0.81 ELANE (0.61) LMNASMN1; SMN2ELANEKMT2AESR1
SCHEMBL650639 0.81 ELANE (0.50) LMNACYP1A2NPC1ELANEKMT2A
SCHEMBL14996055 0.81 ELANE (0.50) LMNACYP1A2NPC1ELANEKMT2A
SCHEMBL10000787 0.81 ELANE (0.47) HSD17B10CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL17617137 0.81 ELANE (0.50) LMNACYP1A2NPC1ELANEKMT2A
SCHEMBL28473798 0.81 LMNA (0.50) LMNACYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL2625475 0.81 ELANE (0.60) HSD17B10LMNACYP1A2CYP2C9CYP2C19
SCHEMBL10359066 0.80 ELANE (0.46) HSD17B10LMNACYP1A2CYP2C9CYP2C19
SCHEMBL97654 0.80 ELANE (0.46) HSD17B10LMNACYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115666554-A Novel Maxi-K potassium channel openers for the treatment of fragile X related disorders 凯鲁斯生物科技有限公司 2023-01-31 CN disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed
US-20100247938-A1 MATERIAL FOR THREE-DIMENSIONAL MODELING, PROCESS FOR PRODUCING THREE-DIMENSIONAL MODEL, AND THREE-DIMENSIONAL MODEL FUJIFILM CORPORATION (JP) 2010-09-30 US disclosed
EP-0694546-B1 Substituted dibenzoxazepine compounds, pharmaceutical compositions and use SEARLE & CO (US) 2001-06-06 EP disclosed
EP-0694545-B1 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use SEARLE & CO (US) 2000-07-26 EP disclosed
US-5576315-A Substituted dibenzoxazepine compounds and methods for treating osteoporosis and ischemia G.D. SEARLE & CO. (US) 1996-11-19 US disclosed
EP-0694546-A2 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use G.D. SEARLE & CO. (US) 1996-01-31 EP disclosed
EP-0694545-A2 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use G.D. SEARLE & CO. (US) 1996-01-31 EP disclosed
US-5464830-A ANALGESICS G. D. SEARLE & CO. (US) 1995-11-07 US disclosed
US-5378840-A Substituted dibenzoxazepine compounds G. D. SEARLE & CO. (US) 1995-01-03 US disclosed
EP-0583421-A1 SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE G.D. SEARLE & CO. (US) 1994-02-23 EP disclosed
WO-1992019617-A2 SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE G.D. SEARLE & CO. (US) 1992-11-12 WO disclosed
EP-0512400-A1 Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use G.D. Searle & Co. (US) 1992-11-11 EP disclosed